Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice

Neurobiology of Aging

Volumn 34, Issue 2, 2013, Pages 589-601

  Szego, Éva M ^a   Outeiro, Tiago F ^a   Kermer, Pawel ^a,b   Schulz, Jörg B ^c,d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY OF AACHEN MEDICAL CENTER   (Germany)

Author keywords

Dementia; Hippocampus; L DOPA; Medial septum; NGF; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLCHOLINESTERASE; ALPHA SYNUCLEIN; DOPAMINE; LEVODOPA; NERVE GROWTH FACTOR; NEUROTROPHIN RECEPTOR P75; PROTEIN TYROSINE KINASE A; SORTILIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; DIAGONAL BAND OF BROCA; DOPAMINE BRAIN LEVEL; HIPPOCAMPAL CA1 REGION; MALE; MOUSE; NERVE GROWTH FACTOR GENE; NONHUMAN; P75NTR GENE; PRIORITY JOURNAL; SORTILIN GENE; TYROSINE RECEPTOR KINASE A GENE;

ALPHA-SYNUCLEIN; ANIMALS; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC NEURONS; DIAGONAL BAND OF BROCA; DOPAMINE; MALE; MICE; MPTP POISONING; NERVE GROWTH FACTOR; PARKINSON DISEASE; RECEPTOR, TRKA; SEPTAL NUCLEI; UP-REGULATION;

EID: 84869091501     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.04.012     Document Type: Article

References (67)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 2003, 60:387-392.
2. Apartis E., Poindessous-Jazat F.R., Lamour Y.A., Bassant M.H. Loss of rhythmically bursting neurons in rat medial septum following selective lesion of septohippocampal cholinergic system. J. Neurophysiol. 1998, 79:1633-1642.
3. Bohnen N.I., Albin R.L. Cholinergic denervation occurs early in Parkinson disease. Neurology 2009, 73:256-257.
4. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., Mathis C.A., Moore R.Y., DeKosky S.T. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 2003, 60:1745-1748.
5. Bouton M.E. Context, time, and memory retrieval in the interference paradigms of Pavlovian learning. Psychol. Bull. 1993, 114:80-99.
6. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
7. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
8. Braak H., Rüb U., Jansen Steur E.N., Del Tredici K., de Vos R.A. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005, 64:1404-1410.
9. Brandner C., Schenk F. Septal lesions impair the acquisition of a cued place navigation task: Attentional or memory deficit?. Neurobiol. Learn. Mem. 1998, 69:106-125.
10. Chang Q., Gold P.E. Impaired and spared cholinergic functions in the hippocampus after lesions of the medial septum/vertical limb of the diagonal band with 192 IgG-saporin. Hippocampus 2004, 14:170-179.
11. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
12. Dalrymple-Alford J.C., Livingston L., MacAskill M.R., Graham C., Melzer T.R., Porter R.J., Watts R., Anderson T.J. Characterizing Mild Cognitive Impairment in Parkinson's Disease. Mov. Disord. 2011, 26:629-636.
13. Day J.C., Fibiger H.C. Dopaminergic regulation of septohippocampal cholinergic neurons. J. Neurochem. 1994, 63:2086-2092.
14. Deguil J., Chavant F., Lafay-Chebassier C., Pérault-Pochat M.C., Fauconneau B., Pain S. Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice. Neurotox. Res. 2010, 17:142-155.
15. Dragoi G., Carpi D., Recce M., Csicsvari J., Buzsáki G. Interactions between hippocampus and medial septum during sharp waves and theta oscillation in the behaving rat. J. Neurosci. 1999, 19:6191-6199.
16. Emre M., Aarsland D., Albanese A., Byrne E.J., Deuschl G., De Deyn P.P., Durif F., Kulisevsky J., van Laar T., Lees A., Poewe W., Robillard A., Rosa M.M., Wolters E., Quarg P., Tekin S., Lane R. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 2004, 351:2509-2518.
17. Francis P.T., Perry E.K. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov. Disord. 2007, 22:S351-S357.
18. Francis P.T., Perry E.K. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov. Disord. 2007, 22:S351-S357.
19. Freichel C., Neumann M., Ballard T., Müller V., Woolley M., Ozmen L., Borroni E., Kretzschmar H.A., Haass C., Spooren W., Kahle P.J. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol. Aging 2007, 28:1421-1435.
20. Fujishiro H., Umegaki H., Isojima D., Akatsu H., Iguchi A., Kosaka K. Depletion of cholinergic neurons in the nucleus of the medial septum and the vertical limb of the diagonal band in dementia with Lewy bodies. Acta Neuropathol. 2006, 111:109-114.
21. Gallagher M., Bakker A., Yassa M.A., Stark C.E. Bridging Neurocognitive Aging and Disease Modification: Targeting Functional Mechanisms of Memory Impairment. Curr. Alzheimer Res. 2010, 7:197-199.
22. German D.C., Liang C.L., Manaye K.F., Lane K., Sonsalla P.K. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience 2000, 101:1063-1069.
23. Härtig W., Seeger J., Naumann T., Brauer K., Brückner G. Selective in vivo fluorescence labelling of cholinergic neurons containing p75(NTR) in the rat basal forebrain. Brain Res. 1998, 808:155-165.
24. Hedreen J.C., Bacon S.J., Price D.L. A modified histochemical technique to visualize acetylcholinesterase-containing axons. J. Histochem. Cytochem. 1985, 33:134-140.
25. Hersi A.I., Kitaichi K., Srivastava L.K., Gaudreau P., Quirion R. Dopamine D-5 receptor modulates hippocampal acetylcholine release. Brain Res. Mol. Brain Res. 2000, 76:336-340.
26. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., Kremmer E., Kretzschmar H.A., Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 2000, 20:6365-6373.
27. Kehagia A.A., Barker R.A., Robbins T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010, 9:1200-1213.
28. Kowsky S., Pöppelmeyer C., Kramer E.R., Falkenburger B.H., Kruse A., Klein R., Schulz J.B. RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20049-20054.
29. Krüger R., Kuhn W., Leenders K.L., Sprengelmeyer R., Müller T., Woitalla D., Portman A.T., Maguire R.P., Veenma L., Schröder U., Schöls L., Epplen J.T., Riess O., Przuntek H. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2001, 56:1355-1362.
30. Lee H.J., Khoshaghideh F., Lee S., Lee S.J. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur. J. Neurosci. 2006, 24:3153-3162.
31. Lim Y., Kehm V.M., Lee E.B., Soper J.H., Li C., Trojanowski J.Q., Lee V.M. α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J. Neurosci. 2011, 31:10076-10087.
32. Lim Y., Kehm V.M., Li C., Trojanowski J.Q., Lee V.M. Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. Exp. Neurol. 2010, 221:86-97.
33. Lisman J.E., Otmakhova N.A. Storage, recall, and novelty detection of sequences by the hippocampus: Elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine. Hippocampus 2001, 11:551-568.
34. Marder K., Tang M.X., Cote L., Stern Y., Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch. Neurol. 1995, 52:695-701.
35. Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988, 8:2804-2815.
36. Mattila P.M., Rinne J.O., Helenius H., Röyttä M. Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol. 1999, 98:157-164.
37. McKeith I., Del Ser T., Spano P., Emre M., Wesnes K., Anand R., Cicin-Sain A., Ferrara R., Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000, 356:2031-2036.
38. Mckeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M., Consortium on D.L.B. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
39. Moro E., Lozano A.M., Pollak P., Agid Y., Rehncrona S., Volkmann J., Kulisevsky J., Obeso J.A., Albanese A., Hariz M.I., Quinn N.P., Speelman J.D., Benabid A.L., Fraix V., Mendes A., Welter M.L., Houeto J.L., Cornu P., Dormont D., Tornqvist A.L., Ekberg R., Schnitzler A., Timmermann L., Wojtecki L., Gironell A., Rodriguez-Oroz M.C., Guridi J., Bentivoglio A.R., Contarino M.F., Romito L., Scerrati M., Janssens M., Lang A.E. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord. 2010, 25:578-586.
40. Morris R.G., Garrud P., Rawlins J.N., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982, 297:681-683.
41. Muenter M.D., Forno L.S., Hornykiewicz O., Kish S.J., Maraganore D.M., Caselli R.J., Okazaki H., Howard F.M., Snow B.J., Calne D.B. Hereditary form of parkinsonism-dementia. Ann. Neurol. 1998, 43:768-781.
42. Niewiadomska G., Baksalerska-Pazera M., Riedel G. The septo-hippocampal system, learning and recovery of function. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:791-805.
43. Ohta K., Kuno S., Inoue S., Ikeda E., Fujinami A., Ohta M. The effect of dopamine agonists: the expression of GDNF, NGF, and BDNF in cultured mouse astrocytes. J. Neurol. Sci. 2010, 291:12-16.
44. Outeiro T.F., Ferreira J. Current and future therapeutic strategies for Parkinson's disease. Curr. Pharm. Des. 2009, 15:3968-3976.
45. Palkovits M., Brownstein M.J. Maps and Guide to Microdissection of the Rat Brain 1988, Elsevier Science, New York.
46. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego.
47. Perry E.K., Curtis M., Dick D.J., Candy J.M., Atack J.R., Bloxham C.A., Blessed G., Fairbairn A., Tomlinson B.E., Perry R.H. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1985, 48:413-421.
48. Perry E.K., Haroutunian V., Davis K.L., Levy R., Lantos P., Eagger S., Honavar M., Dean A., Griffiths M., McKeith I.G., et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994, 5:747-749.
49. Rodriguez-Oroz M.C., Obeso J.A., Lang A.E., Houeto J.L., Pollak P., Rehncrona S., Kulisevsky J., Albanese A., Volkmann J., Hariz M.I., Quinn N.P., Speelman J.D., Guridi J., Zamarbide I., Gironell A., Molet J., Pascual-Sedano B., Pidoux B., Bonnet A.M., Agid Y., Xie J., Benabid A.L., Lozano A.M., Saint-Cyr J., Romito L., Contarino M.F., Scerrati M., Fraix V., Van Blercom N. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005, 128:2240-2249.
50. Scatton B., Simon H., Le Moal M., Bischoff S. Origin of dopaminergic innervation of the rat hippocampal formation. Neurosci. Lett. 1980, 18:125-131.
51. Schindowski K., Belarbi K., Buée L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 2008, 1(7 Suppl):43-56.
52. Shin C.W., Kim H.J., Park S.S., Kim S.Y., Kim J.Y., Jeon B.S. Two Parkinson's Disease Patients With alpha-Synuclein Gene Duplication and Rapid Cognitive Decline. Mov. Disord. 2010, 25:957-959.
53. Sidhu A., Wersinger C., Moussa C.E., Vernier P. The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann. N. Y. Acad. Sci. 2004, 1035:250-270.
54. Sousa V.L., Bellani S., Giannandrea M., Yousuf M., Valtorta F., Meldolesi J., Chieregatti E. {alpha}-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. Mol. Biol. Cell 2009, 20:3725-3739.
55. Spira P.J., Sharpe D.M., Halliday G., Cavanagh J., Nicholson G.A. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 2001, 49:313-319.
56. Squire L.R., Stark C.E., Clark R.E. The medial temporal lobe. Annu. Rev. Neurosci. 2004, 27:279-306.
57. Szego É.M., Barabás K., Balog J., Szilágyi N., Korach K.S., Juhász G., Abrahám I.M. Estrogen induces estrogen receptor alpha-dependent cAMP response element-binding protein phosphorylation via mitogen activated protein kinase pathway in basal forebrain cholinergic neurons in vivo. J. Neurosci. 2006, 26:4104-4110.
58. Szego É.M., Csorba A., Janáky T., Kékesi K.A., Abrahám I.M., Mórotz G.M., Penke B., Palkovits M., Murvai U., Kellermayer M.S., Kardos J., Juhász G.D. Effects of estrogen on beta-amyloid-induced cholinergic cell death in the nucleus basalis magnocellularis. Neuroendocrinology 2011, 93:90-105.
59. Szego É.M., Gerhardt E., Outeiro T.F., Kermer P. Dopamine-depletion and increased α-synuclein load induce degeneration of cortical cholinergic fibers in mice. J. Neurol. Sci. 2011, 310:90-95.
60. Szego É.M., Gerhardt E., Kermer P., Schulz J.B. A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice. Neurobiol. Dis. 2012, 45:591-600.
61. Teng K.K., Felice S., Kim T., Hempstead B.L. Understanding proneurotrophin actions: Recent advances and challenges. Dev. Neurobiol. 2010, 70:350-359.
62. Tiraboschi P., Hansen L.A., Alford M., Sabbagh M.N., Schoos B., Masliah E., Thal L.J., Corey-Bloom J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407-411.
63. Venda L.L., Cragg S.J., Buchman V.L., Wade-Martins R. α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2004, 33:559-568.
64. Vivacqua G., Casini A., Vaccaro R., Fornai F., Yu S., D'Este L. Different sub-cellular localization of alpha-synuclein in the C57BL\6J mouse's central nervous system by two novel monoclonal antibodies. J. Chem. Neuroanat. 2011, 41:97-110.
65. Woods S.P., Tröster A.I. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J. Int. Neuropsychol. Soc. 2003, 9:17-24.
66. Zaborszky L., Cullinan W.E. Direct catecholaminergic-cholinergic interactions in the basal forebrain. IDopamine-beta-hydroxylase- and tyrosine hydroxylase input to cholinergic neurons. J. Comp. Neurol. 1996, 374:535-554.
67. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.